New insights in mast cell modulation by palmitoylethanolamide

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 1, 2013, Pages 78-83

  de Filippis, D ^a,b   Negro, L ^a,b   Vaia, M ^a   Cinelli, M P ^a   Iuvone, T ^a  

^a Dept of Experimental Pharmacology ^*  (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Autocoid local injury antagonism; Endocannabinoids; Homeostasis; Inflammation; Mast cells; Pain; Palmitoylethanolamide

Indexed keywords

CANNABINOID 2 RECEPTOR; CD31 ANTIGEN; CHYMASE; GLYCOSIDE; HISTAMINE; LEUKOTRIENE C4; NERVE GROWTH FACTOR; PALMIDROL; POLYDATIN; PROSTAGLANDIN D2; SEROTONIN; TRYPTASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANGIOGENESIS; ATOPIC DERMATITIS; CELL ACTIVATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DRUG EFFECT; EDEMA; GRANULOMA; HUMAN; HYPERALGESIA; HYPERSENSITIVITY; IMMUNE RESPONSE; INFLAMMATION; MAST CELL; MAST CELL DEGRANULATION; NEUROPATHIC PAIN; NONHUMAN; PASSIVE SKIN ANAPHYLAXIS; PELVIS PAIN SYNDROME; PROTEIN EXPRESSION; REVIEW; SKIN DISEASE;

EID: 84875290555     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527311312010013     Document Type: Review

References (64)

1. Lambert, D.; Vandevoorde, S.; Jonsson, K.O.; Fowler, C.J. The palmitoylethanolamide family: a new class of anti-inflammatory agents. Curr. Med. Chem., 2002, 9,663-674.
2. Franklin, A.; Parmentier-Batteur, S.; Walter, L.; Greenberg, D.A.; Stella, N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J. Neurosci., 2003, 23, 7767-7775.
3. Muccioli, G.G.; Stella, N. Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology., 2008, 54, 16-22.
4. Ueda, N.; Tsuboi, K.; Uyama, T. N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). Prog. Lipid Res., 2010, 49, 299-315.
5. Ueda, N. Endocannabinoid hydrolases. Prostaglandins Other Lipid Mediat., 2002, 68-69, 521-534.
6. Costa, B.; Comelli, F.; Bettoni, I.; Colleoni, M.P.; Giagnoni, G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARgamma receptors and neurotrophic factors. Pain. 2008, 139, 541-50.
7. Farquhar-Smith, W.P.; Jaggar, S.I.; Rice, A.S. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain., 2002, 97,11-21
8. Calignano, A.; La Rana, G.; Giuffrida, A.; Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature., 1998, 394, 277-281.
9. Romero, T.R.; Galdino, G.S.; Silva, G.C.; Resende, L.C.; Perez, A.C.; Cortes, S.F.; Duarte, I.D. Involvement of the L-arginine/nitric oxide/cyclic guanosine monophosphate pathway in peripheral antinociception induced by N-palmitoyl-ethanolamine in rats. J. Neurosci. Res., 2012, 90, 1474-1479.
10. Jaggar, S.I.; Hasnie, F.S.; Sellaturay, S.; Rice, A.S. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 1998, 76, 189-199.
11. De Petrocellis, L.; Harrison, S.; Bisogno, T.; Tognetto, M.; Brandi, I.; Smith, G.D.; Creminon, C.; Davis, J.B.; Geppetti, P.; Di Marzo, V. The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J. Neurochem., 2001, 77, 1660-1663.
12. O'Sullivan, S.E. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br. J. Pharmacol., 2007, 152, 576-582.
13. Mackie, K.; Stella, N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J. 2006, 8, E298-306.
14. Cantarella, G.; Scollo, M.; Lempereur, L.; Saccani-Jotti, G.; Basile, F.; Bernardini, R. Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem. Pharmacol., 2011, 82, 380-388.
15. Aloe, L.; Leon, A.; Levi-Montalcini, R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents and actions 1993;39 Spec No: C145-C147.
16. Aloe, L.; Leon, A.; Levi-Montalcini, R. A proposed autacoids mechanism controlling mastocyte behavior. Agents Actions 1993; 39: C145-7.
17. Facci, L.; Dal Toso, R.; Romanello, S.; Buriani, A.; Skaper, S.D.; Leon, A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U S A., 1995, 92, 3376-3380.
18. Theoharides, T.C.; Alysandratos, K.D.; Angelidou, A.; Delivanis, D.A.; Sismanopoulos, N.; Zhang, B.; Asadi, S.; Vasiadi, M.; Weng, Z.; Miniati, A.; Kalogeromitros, D. Mast cells and inflammation. Biochim. Biophys. Acta, 2012, 1822, 21-33.
19. Jamur, M.C.; Oliver, C. Origin, maturation and recruitment of mast cell precursors. Front Biosci. (Schol Ed), 2011, 3,1390-406.
20. Chan, A.; Cooley, M.A.; Collins, A.M. Mast cells in the rat liver are phenotypically heterogeneous and exhibit features of immaturity. Immunol. Cell Biol., 2001, 79, 35-40.
21. Lee, Y.M.; Jippo, T.; Kim, D.K.; Katsu, Y.; Tsujino, K.; Morii, E.; Kim, H.M.; Adachi, S.; Nawa, Y.; Kitamura, Y. Alteration of protease expression phenotype of mouse peritoneal mast cells by changing the microenvironment as demonstrated by in situ hybridization histochemistry. Am. J. Pathol., 1998, 153, 931-6.
22. De Filippis, D.; D'Amico, A.; Iuvone, T. Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. Journal of Endocrinology. 2008, 20, 20-25.
23. Kumar, V.; Sharma, A. Mast cells: emerging sentinel innate immune cells with diverse role in immunity. Mol. Immunol., 2010, 48, 14-25.
24. Maltby, S.; Khazaie, K.; McNagny, K.M. Mast cells in tumor growth: Angiogenesis, tissue remodelling and immune-modulation. Biochim. Biophys. Acta, 2009, 1796, 19-26.
25. Boyce, J.A. Mast cells: beyond IgE. J. Allergy Clin. Immunol., 2003, 111, 24-32;
26. Kalesnikoff, J.; Galli, S.J. New developments in mast cell biology. Nat. Immunol., 2008, 9, 1215-23.
27. Kalesnikoff, J.; Galli, S.J. Anaphylaxis: mechanisms of mast cell activation. Chem. Immunol Allergy. 2010, 95, 45-66.
28. Amin, K. The role of mast cells in allergic inflammation. Respir. Med., 2012, 106, 9-14.
29. Maxová, H. Vasilková, M.; Novotná, J.; Vajnerová, O.; Bansová, A.; Vízek, M.; Herget, J. Prevention of mast cell degranulation by disodium cromoglycate delayed the regression of hypoxic pulmonary hypertension in rats. Respiration. 2010, 80, 335-339.
30. Sanz, M.L.; Gamboa, P.M.; García-Figueroa, B.E.; Ferrer, M. In vitro diagnosis of anaphylaxis. Chem. Immunol. Allergy. 2010, 95, 125-140.
31. Skaper, S.D.; Facci, L.; Romanello, S.; Leon, A. Mast cell activation causes delayed neurodegeneration in mixed hippocampalcultures via the nitric oxide pathway. J. Neurochem. 1996 Mar,66, 1157-1166.
32. Bisogno, T., Maurelli, S.; Melck, D.; De Petrocellis, L.; Di Marzo, V. Biosynthesis, uptake, and degradation of anandamide andpalmitoylethanolamide in leukocytes. J. Biol. Chem., 1997, 272, 3315-3323.
33. Jacobsson, S.O.; Fowler, C.J. Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. Br. J. Pharmacol., 2001, 132,1743-1754.
34. Maccarrone, M.; De Petrocellis, L.; Bari, M.; Fezza, F.; Salvati, S.; Di Marzo, V.; Finazzi-Agrò, A. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch. Biochem. Biophys., 2001, 393, 321-328.
35. Fowler, C.J.; Tiger, G.; López-Rodríguez, M.L.; Viso, A.; Ortega-Gutiérrez, S.; Ramos, J.A. Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin. J. Enzyme Inhib. Med. Chem., 2003, 18, 225-231
36. Lau, A.H.; Chow, S.S. Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells. Eur. J. Pharmacol., 2003, 464, 229-235.
37. Bueb, J.L.; Lambert, D.M.; Tschirhart, E.J. Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro. Biochim. Biophys. Acta. 2001, 1538, 252-259.
38. Granberg, M.; Fowler, C.J.; Jacobsson, S.O. Effects of the cannabimimetic fatty acid derivatives 2-arachidonoylglycerol, anandamide, palmitoylethanolamide and methanandamide upon IgE-dependent antigen-induced beta-hexosaminidase, serotonin and TNF release from rat RBL-2H3 basophilic leukaemia cells Naunyn Schmiedebergs. Arch. Pharmacol., 2001, 364, 66-73.
39. Cerrato, S.; Brazis, P.; della Valle, M.F.; Miolo, A.; Puigdemont, A. Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells. Vet. Immunol. Immunopathol., 2010, 133, 9-15.
40. Galli, S.J. New concepts about the mast cell. N. Engl. J. Med., 1993, 328, 257-265.
41. Mita, H.; Ishii, T.; Yamada, T.; Akiyama, K.; Shida, T. Further characterization of dispersed human sinus mast cells. Life Sci., 1993, 53, 775-782.
42. Shanahan, F.; Lee, T.D.; Bienenstock, J.; Befus, A.D. Mast cell heterogeneity: effect of anti-allergic compounds on neuropeptide-induced histamine release. Int. Arch. Allergy Appl. Immunol., 1986, 80, 424-426.
43. Bissonnette, E.Y.; Befus, A.D. Anti-inflammatory effect of beta 2-agonists: inhibition of TNF-alpha release from human mast cells. J. Allergy Clin. Immunol., 1997, 100, 825-831.
44. Mazzari, S.; Canella, R.; Petrelli, L.; Marcolongo, G.; Leon, A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol., 1996, 300, 227-236.
45. Jonsson, K.O.; Persson, E.; Fowler, C.J. The cannabinoid CB2 receptor selective agonist JWH133 reduces mast cell oedema in response to compound 48/80 in vivo but not the release of beta-hexosaminidase from skin slices in vitro. Life Sci., 2006, 78, 598-606.
46. Russo, A.; Russo, G.; Peticca, M.; Pietropaolo, C.; Di Rosa, M.; Iuvone, T. Inhibition of granuloma-associated angiogenesis by controllino mast cell mediator release: role of mast cell protease-5. Br. J. Pharmacol., 2005, 145, 24-33.
47. De Filippis, D.; D'Amico, A.; Cipriano, M.; Petrosino, S.; Orlando, P.; Di Marzo, V.; Iuvone, T. Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. Pharmacol. Res., 2010, 61, 321-8.
48. De Filippis, D.; Luongo, L.; Cipriano, M.; Palazzo, E.; Cinelli, M.P.; de Novellis, V.; Maione, S.; Iuvone, T. Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol. Pain., 2011, 7, 3.
49. De Filippis, D.; D'Amico, A.; Cinelli, M.P.; Esposito, G.; Di Marzo, V.; Iuvone, T. Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in carrageenin granuloma model in rat. J. Cell Mol. Med., 2009, 131086-131095.
50. Esposito, E.; Paterniti, I.; Mazzon, E.; Genovese, T.; Di Paola, R.; Galuppo, M.; Cuzzocrea, S. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav. Immun., 2011, 25, 1099-1112.
51. Keppel Hesselink, M.J. New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide The Open Pain Journal, 2012, 5, 12-23
52. Masek, K.; Perlík, F.; Klíma, J.; Kahlich, R. Prophylactic efficacy of N-2-hydroxyethyl palmitamide (impulsin) in acute respiratory tract infections. Eur. J. Clin. Pharmacol., 1974, 7, 415-419
53. Scarampella, F.; Abramo, F.; Noli, C. Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Vet Dermatol., 2001, 12, 29-39.
54. Cerrato, S.; Brazis, P.; della Valle, M.F.; Miolo, A.; Petrosino, S.; Di Marzo, V.; Puigdemont, A. Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. Vet J., 2012, 191, 377-382.
55. Indraccolo, U.; Barbieri, F. 2010 Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations. Eur. J. Obstet. Gynecol. Reprod. Biol., 2010, 150, 76-79.
56. Truini, A.; Biasiotta, A.; Di Stefano, G.; La Cesa, S.; Leone, C.; Cartoni, C.; Federico, V. Petrucci, M.T. Cruccu, G. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol. Disord Drug Targets, 2011, 10, 916-920.
57. Pulvirenti, N.; Nasca, M.R.; Micali, G. Topical adelmidrol 2% emulsion, a novel aliamide, in the treatment of mild atopic dermatitis in pediatric subjects: a pilot study. Acta Dermatovenerol. Croat., 2007, 15, 80-83.
58. Anand, P.; Singh, B.; Jaggi, A.S.; Singh, N. Mast cells: an expanding pathophysiological role from allergy to other disorders. Naunyn Schmiedebergs Arch. Pharmacol., 2012, 385, 657-670.
59. Rao, K.N.; Brown, M.A. Mast cells: multifaceted immune cells with diverse roles in health and disease. Ann. N. Y. Acad. Sci., 2008, 1143, 83-104.
60. Holdsworth, S.R.; Summers, S.A. Role of Mast Cells in Progressive Renal Diseases. J. Am. Soc. Nephrol., 2008, 19, 2254-2261.
61. Liu, J.; Zhang, Y.; Zhao, J.; Yang, Z.; Li, D.; Katirai, F.; Huang, B. Mast cell: insight into remodeling a tumor microenvironment. Cancer Metastasis Rev., 2011, 30, 177-184.
62. Lindsberg, P.J.; Strbian, D.; Karjalainen-Lindsberg, M.L. Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage. J. Cereb. Blood Flow Metab., 2010, 30, 689-702.
63. Skaper, S.D.; Giusti, P.; Facci, L. Microglia and mast cells: a double act in neuroinflammation The FASEB Journal article fj.11-197194.
64. Zhang, J.; Shi, G.P. Mast cells and metabolic syndrome. Biochim. Biophys. Acta, 2012, 1822, 14-20.